✦ LIBER ✦

Tamoxifen Use in Postmenopausal Breast Cancer: CYP2D6 Matters

✍ Scribed by Brauch, H.; Schroth, W.; Goetz, M. P.; Murdter, T. E.; Winter, S.; Ingle, J. N.; Schwab, M.; Eichelbaum, M.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CYP2D6 and tamoxifen: DNA matters in bre

✍ Hoskins, Janelle M.; Carey, Lisa A.; McLeod, Howard L. 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 422 KB

Tamoxifen Metabolite Concentrations, CYP

✍ Madlensky, L; Natarajan, L; Tchu, S; Pu, M; Mortimer, J; Flatt, S W; Nikoloff, D 📂 Article 📅 2011 🏛 Nature Publishing Group 🌐 English ⚖ 169 KB

Impact of CYP2D6 polymorphisms in tamoxi

✍ T. Ramón y Cajal; A. Altés; L. Paré; E. del Rio; C. Alonso; A. Barnadas; M. Baig 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 177 KB

The CYP2D6*4 polymorphism affects breast

✍ Monique J. Bijl; Ron H. N. van Schaik; Laureen A. Lammers; Albert Hofman; Arnold 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 207 KB

Concurrent use of tamoxifen with CYP2D6

✍ Laurent Azoulay; Sophie Dell’Aniello; Laetitia Huiart; Guillaume Galbaud du Fort 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 207 KB

CYP2D6 Genotype and Tamoxifen Response i

✍ Regan, M. M.; Leyland-Jones, B.; Bouzyk, M.; Pagani, O.; Tang, W.; Kammler, R.; 📂 Article 📅 2012 🏛 Oxford University Press 🌐 English ⚖ 529 KB